Invesco’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-159,898
| Closed | -$3.43M | – | 3852 |
|
|
2026
Q1 | $3.43M | Buy |
159,898
+35,904
| +29% | +$506K | ﹤0.01% | 2328 |
|
|
2025
Q4 | $1.16M | Buy |
123,994
+25,952
| +26% | +$217K | ﹤0.01% | 2850 |
|
|
2025
Q3 | $691K | Buy |
98,042
+29,535
| +43% | +$203K | ﹤0.01% | 3103 |
|
|
2025
Q2 | $445K | Buy |
68,507
+22,083
| +48% | +$152K | ﹤0.01% | 3203 |
|
|
2025
Q1 | $368K | Buy |
46,424
+13,636
| +42% | +$147K | ﹤0.01% | 3282 |
|
|
2024
Q4 | $415K | Buy |
32,788
+798
| +2% | +$11.1K | ﹤0.01% | 3316 |
|
|
2024
Q3 | $446K | Buy |
31,990
+766
| +2% | +$10.9K | ﹤0.01% | 3280 |
|
|
2024
Q2 | $430K | Sell |
31,224
-419
| -1% | -$6.13K | ﹤0.01% | 3338 |
|
|
2024
Q1 | $523K | Buy |
31,643
+285
| +0.9% | +$4.26K | ﹤0.01% | 3313 |
|
|
2023
Q4 | $458K | Buy |
31,358
+12,196
| +64% | +$148K | ﹤0.01% | 3273 |
|
|
2023
Q3 | $235K | Buy |
19,162
+3,068
| +19% | +$40K | ﹤0.01% | 3535 |
|
|
2023
Q2 | $192K | Buy |
+16,094
| New | +$210K | ﹤0.01% | 3623 |
|
|
2022
Q3 | – | Sell |
-97,024
| Closed | -$1.74M | – | 4001 |
|
|
2022
Q2 | $1.74M | Buy |
+97,024
| New | +$1M | ﹤0.01% | 2766 |
|
Other funds holding DAWN
Invesco's DAWN Position: Q2 2026 in Review
Invesco sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 159,898 shares — an estimated $3.43M sold.
Invesco first reported a position in DAWN in Q2 2022 and held it in 13 quarters. The position peaked at $3.43M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Invesco reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Invesco sold 159,898 Day One Biopharmaceuticals shares in Q2 2026, an estimated $3.43M.
- Invesco first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 13 quarters.
- Invesco's Day One Biopharmaceuticals position peaked at $3.43M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.